These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 27025218)

  • 1. [Effect of the German Act on the reform of the market for medicinal products (AMNOG) on the quality of neurological and psychiatric treatment].
    Hamer H; Meyer-Lindenberg A
    Nervenarzt; 2016 Apr; 87(4):351-2. PubMed ID: 27025218
    [No Abstract]   [Full Text] [Related]  

  • 2. [Significance of the German Act on the Reform of the Market for Medicinal Products for psychopharmacotherapy].
    Gründer G
    Nervenarzt; 2016 Apr; 87(4):356-66. PubMed ID: 26983820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Earlier value assessment of pharmaceutical products and medical science].
    Selbmann HK
    Nervenarzt; 2016 Apr; 87(4):353-5. PubMed ID: 27000270
    [No Abstract]   [Full Text] [Related]  

  • 4. [Actual medical care situation and therapeutic needs in multiple sclerosis: Impact of the Pharmaceutical Market Restructuring Act (AMNOG)].
    Bittner S; Meuth SG
    Nervenarzt; 2016 Apr; 87(4):394-401. PubMed ID: 27023842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The new German drug market law AMNOG from a child and adolescent psychiatry perspective].
    Dittmann RW
    Nervenarzt; 2016 Apr; 87(4):367-75. PubMed ID: 26992908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Requirements for drug approval and additional benefits assessment: Regulatory aspects and experiences].
    Broich K; Löbker W; Schulte A; Beinlich P; Müller T
    Nervenarzt; 2016 Apr; 87(4):376-85. PubMed ID: 27003322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Impact of early benefit assessment on patients with epilepsy in Germany: Current healthcare provision and therapeutic needs].
    Strzelczyk A; Hamer HM
    Nervenarzt; 2016 Apr; 87(4):386-93. PubMed ID: 26927680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Applying market power--the BHCAG is flexing its muscle. Business Health Care Action Group.
    Allen T
    Minn Med; 1994 Dec; 77(12):6-7, 52. PubMed ID: 7823884
    [No Abstract]   [Full Text] [Related]  

  • 9. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma.
    Wang Z
    Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001
    [No Abstract]   [Full Text] [Related]  

  • 10. Outcomes assessment in health care reform: promise and limitations.
    Mariner WK
    Am J Law Med; 1994; 20(1-2):37-57. PubMed ID: 7801980
    [No Abstract]   [Full Text] [Related]  

  • 11. Raising the bar for market authorisation of new drugs.
    Naci H; Cylus J; Vandoros S; Sato A; Perampaladas K
    BMJ; 2012 Aug; 345():e4261. PubMed ID: 22872693
    [No Abstract]   [Full Text] [Related]  

  • 12. Evaluation of a possible predictor for Federal Joint Committee decisions on early benefit assessments according to the German act on the reform of the market for medicinal products.
    Schwander B; Banz K; Kaier K; Walzer S
    Health Policy; 2014 Sep; 117(3):334-44. PubMed ID: 25059744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug safety reform at the FDA--pendulum swing or systematic improvement?
    McClellan M
    N Engl J Med; 2007 Apr; 356(17):1700-2. PubMed ID: 17435081
    [No Abstract]   [Full Text] [Related]  

  • 14. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
    Dinh TQ
    Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmaceuticals and medical devices: FDA oversight.
    Berry MD
    Issue Brief Health Policy Track Serv; 2013 Dec; ():1-123. PubMed ID: 24482893
    [No Abstract]   [Full Text] [Related]  

  • 16. [The therapy allergens ordinance ("Therapieallergene-Verordnung"). Background and effects].
    Englert L; May S; Kaul S; Vieths S
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2012 Mar; 55(3):351-7. PubMed ID: 22373848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The regulatory framework for complementary and alternative medicines in Europe].
    Knöss W; Stolte F; Reh K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):771-8. PubMed ID: 18584103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Psychiatric psychotherapeutic psychosomatic treatment by the hospital: framework for the development of a multi-sector budget for regional mandatory care].
    Kruckenberg P; Beine K; Aderhold V; Bock T; Bührig M; Deister A; Driessen M; Elsässer-Gaismaier HP; Grampp P; Greve N; Heinz A; Heinze M; Heisler M; Küthmann A; Kunze H; Lucht M; Niedermeyer U; Obliers W; Schütze W; Stock M
    Psychiatr Prax; 2009 Jul; 36(5):246-9. PubMed ID: 19582663
    [No Abstract]   [Full Text] [Related]  

  • 19. An insider's perspective: defense of the pharmaceutical industry's marketing practices.
    Johar K
    Albany Law Rev; 2012-2013; 76(1):299-334. PubMed ID: 23577377
    [No Abstract]   [Full Text] [Related]  

  • 20. [GKV Health Reform 2000--cabinet proposal for the regulation. Combined position of the German Society of Psychiatry, Psychotherapy and Neurology and the Study Group for Neuropsychopharmacology and Pharmacopsychiatry].
    Fritze J; Sass H; Möller HJ
    Nervenarzt; 1999 Aug; 70(8):766-71. PubMed ID: 10483581
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.